|
May 1
|
Update: Johnson & Johnson Announces $6.48 Billion Plan for Unit to Resolve Ovarian Cancer Talc Claims
|
|
May 1
|
Johnson & Johnson moves forward with $6.475 billion settlement of talc cancer lawsuits
|
|
May 1
|
UPDATE 2-J&J advances $6.48 billion settlement of talc cancer lawsuits
|
|
May 1
|
J&J subsidiary proposes paying about $6.48B over 25 years to settle talc ovarian cancer lawsuits
|
|
May 1
|
J&J advances $6.48 billion settlement of talc cancer lawsuits
|
|
May 1
|
Johnson & Johnson Announces Plan by its Subsidiary, LLT Management LLC, to Resolve All Current and Future Ovarian Cancer Talc Claims Through a Consensual "Prepackaged" Reorganization
|
|
May 1
|
Johnson & Johnson Has a New Plan to Settle Talc Bankruptcy
|
|
May 1
|
J&J advances $6.475 billion settlement of talc cancer lawsuits
|
|
Apr 30
|
Addex stock tanks after lead drug flops in Phase II epilepsy trial
|
|
Apr 29
|
J&J, Bristol Myers lose challenges to US drug price negotiation program
|
|
Apr 29
|
Johnson & Johnson-Partnered Addex Therapeutics' Epilepsy Candidate Fails Mid-Stage Study, Stock Tanks
|
|
Apr 29
|
Johnson & Johnson Is a King of Dividend Safety
|
|
Apr 29
|
Johnson & Johnson's (NYSE:JNJ) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?
|
|
Apr 28
|
Dividend Stock Portfolio For Income: Top 15 Stocks
|
|
Apr 28
|
2 Top Growth Stocks to Buy Right Now and Hold Forever
|
|
Apr 28
|
Better Dividend Stock: AbbVie or Johnson & Johnson?
|
|
Apr 27
|
10 Best Long Term Low Risk Stocks to Buy
|
|
Apr 27
|
Johnson & Johnson Stock: Buy, Sell, or Hold?
|
|
Apr 26
|
AbbVie (ABBV) Beats on Q1 Earnings & Sales, Ups '24 EPS View
|
|
Apr 26
|
Are You Looking for a High-Growth Dividend Stock?
|